Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease

American Journal of Pathology

Volumn 149, Issue 4, 1996, Pages 1229-1239

  Estellés, Amparo ^a   Grancha, Salvador ^a   Gilabert, Juan ^a   Thinnes, Terri ^b   Chirivella, Melitina ^a   España, Francisco ^a   Aznar, Justo ^a   Loskutoff, David J ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VITRONECTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; SPONTANEOUS ABORTION; TROPHOBLASTIC DISEASE;

FEMALE; HUMANS; HYDATIDIFORM MOLE; PLACENTA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN INACTIVATORS; PREGNANCY; TISSUE POLYPEPTIDE ANTIGEN; UTERINE NEOPLASMS;

EID: 0029819734     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Albrechtsen OK: The fibrinolytic activity on the human endometrium. Acta Endocrinol 1956, 23:207-210
2. Kliman HJ, Contifaris C, Feinberg RF, Strauss JF III: In vitro models utilizing human tissues. Implantation. Edited by K Yoshinaga. Boston, Adams Blastocyst Publishing Group, 1989, pp 83-91
3. Loskutoff DJ, Sawdey M, Mimuro J: Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1988, 9:87-115
4. Loskutoff DJ: Regulation of PAI-1 gene expression. Fibrinolysis 1991, 5:197-206
5. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 1987, 69:381-387
6. Åstedt B, Lecander I, Ny T: The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1987, 1:203-208
7. Bachmann F: The enigma PAI-2: gene expression, evolutionary and functional aspects. Thromb Haemost 1995, 74:172-179
8. Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann WF: Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987, 69:460-466
9. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR: Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989, 74:1332-1338
10. Gilabert J, Estellés A, Aznar J, España F, Andrés C, Santos T, Vallés J: Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia. Thromb Haemost 1990, 63:361-366
11. Inglis TCM, Stuart J, George AJ, Dacies J: Haemostatic and rheological changes in normal pregnancy and preeclampsia. Br J Haematol 1982, 50:461-465
12. Graeff H, Von Hugo R, Schrock R: Recent aspects of hemostasis, hematology and hemorrheology in preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1984, 17:91-102
13. Aznar J, Gilabert J, Estellés A, España F: Fibrinolytic activity and protein C in preeclampsia. Thromb Haemost 1986, 55:314-317
14. Estellés A, Gilabert J, España F, Aznar J, Gómez-Lechón MJ: Fibrinolysis in pre-eclampsia. Fibrinolysis 1987, 1:209-214
15. Estellés A, Gilabert J, España F, Aznar J, Galbis M: Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991, 165:138-142
16. Ballegeer V, Spitz B, Kieckens L, Moreau H, Van Assche A, Collen D: Predictive value of increased plasma levels of fibronectin in gestational hypertension. Am J Obstet Gynecol 1989, 161:432-436
17. de Boer K, Lecander J, Ten Cate JW, Bom JJJ, Treffers PE: Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988, 158:518-522
18. Gilabert J, Estellés A, Ayuso MJ, España F, Chirivella M, Grancha S, Micó JM, Aznar J: Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest 1994, 38:157-162
19. Cunningham FG, MacDonald PC, Gant NF: Disease and abnormalities of the placenta and fetal membranes. Williams' Obstetrics, ed 18. Norwalk, CT, Appleton and Lange, 1987, pp 533-559
20. Benirschke K, Kaufmann P: Molar pregnancies. Pathology of the Human Placenta. Edited by K Benirschke, P Kaufmann. New York, Springer-Verlag, 1990, pp 782-815
21. Tsakok FHM, Koh S, Ratnam SS: Coagulation and fibrinolysis in intact hydatidiform molar pregnancy. Br Med J 1976, 2:1481-1484
22. Ratnoff OD: Disseminated intravascular coagulation during pregnancy. Haemostasis and Thrombosis in Obstetrics and Gynaecology. Edited by A Greer, AGG Turpie, DC Forbes. London, Chapman and Hall, 1992, pp 115-142
23. Feinberg RF, Kao L-C, Haimowitz JE, Queenan JT Jr, Wun T-C, Strauss JF III, Kliman HJ: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts: PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 1989, 61:20-26
24. Åstedt B, Hagerstrand I, Lecander I: Cellular localization in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986, 56:63-65
25. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, España F, Loskutoff DJ, Schleef RR: Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994, 84:143-150
26. Arkwright PD, Rademacher TW, Dwek RA, Redman CWG: Preeclampsia is associated with an increase in trophoblast glycogen content and glycogen synthase activity, similar to that found in hydatidiform moles. J Clin Invest 1993, 91:2744-2753
27. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B: Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia, and hydatidiform mole. Br J Obstet Gynaecol 1993, 100:370-374
28. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Berhaus GM, Collen D: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988, 30:15454-15461
29. Mimuro J, Loskutoff DJ: Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: evidence that the protein is vitronectin. J Biol Chem 1989, 264:936-939
30. Radtke K, Wenz K, Heimburger N: Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta: evidence for vitronectin/PAI-2 complexes in human placenta extract. Biol Chem Hoppe-Seyler 1990, 371: 1119-1127
31. Watanabe T, Araki M, Mimuro J, Tamada T, Sakata Y: Fibrinolytic components in fetal membranes and amniotic fluid. Am J Obstet Gynecol 1993, 168:1283-1289
32. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ: The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 1990, 110:155-163
33. Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ: The somatomedin B domain of vitronectin: structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994, 269:2659-2666
34. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ: Cellular localization of type 1 plasminogen activator inhibitor in renal tissue from normal and endotoxin-treated mice. Am J Pathol 1993, 142:59-70
35. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992, 89:6998-7002
36. Jenne D, Stanley KK: Molecular cloning of S-protein, a link between complement, coagulation, and cell-substrate adhesion. EMBO J 1985, 4:3153-3157
37. Ye RD, Wun T, Sadler JE: cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987, 262: 3718-3725
38. Jaattela M, Kuusela P, Sakkela E: Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest 1988, 58:48-52
39. Chen H, Yang Y, Hu X, Yelavarthi KK, Fishback JL, Hunt JS: Tumor necrosis factor-α mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 1991, 139:327-335
40. β, human leukocyte antigen HLA-DRα, and transforming growth factor-β expression in endometrium, placenta, and placental membranes. Am J Obstet Gynecol 1990, 163:1430-1437
41. Taniguchi T, Matsuzaki N, Kameda T, Shimoya K, Jo T, Saji F, Tanizawa O: The enhanced production of placental interleukin-1 during labor and intrauterine infection. Am J Obstet Gynecol 1990, 165:131-137
42. Wolf HK, Zarnegar R, Oliver L, Michalopoulos GK: Hepatocyte growth factor in human placenta and trophoblastic disease. Am J Pathol 1991, 138:1035-1043
43. Medcalf RL, Kruithof EKO, Schleuning W-D: Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 1988, 168: 751-759
44. Hamilton JA, Wotja J, Gallichio M, McGrath K, Filonzi EL: Contrasting effects of transforming growth factor-β and IL-1 on the regulation of plasminogen activator inhibitors in human synovial fibroblasts. J Immunol 1993, 151:5154-5161
45. Hamilton JA, Whitty GA, Wotja J, Gallichio M, McGrath K, Ianches G: Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell Immunol 1993, 152:7-17
46. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J: Regulation of PAI-1 gene expression in vivo. Fibrinolytic Inhibitors: Cellular, Biological, and Clinical Aspects. Edited by J Aznar, J Gilabert, A Estellés. Spain, Garsi-Masson, 1994, pp 8-17